Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,762,007
  • Shares Outstanding, K 43,974
  • Annual Sales, $ 36,470 K
  • Annual Income, $ -180,860 K
  • 60-Month Beta 0.43
  • Price/Sales 74.27
  • Price/Cash Flow N/A
  • Price/Book 7.66
Trade IMCR with:

Options Overview Details

View History
  • Implied Volatility 81.28% ( +2.33%)
  • Historical Volatility 50.22%
  • IV Percentile 35%
  • IV Rank 50.26%
  • IV High 131.49% on 07/19/22
  • IV Low 30.55% on 12/17/21
  • Put/Call Vol Ratio 0.93
  • Today's Volume 29
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 2,374
  • Open Int (30-Day) 1,913

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.08
  • Number of Estimates 6
  • High Estimate 0.16
  • Low Estimate -0.33
  • Prior Year -1.21
  • Growth Rate Est. (year over year) +93.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.63 +15.64%
on 11/03/22
69.06 -10.19%
on 11/21/22
+5.15 (+9.05%)
since 11/01/22
3-Month
38.90 +59.43%
on 09/13/22
69.06 -10.19%
on 11/21/22
+10.12 (+19.50%)
since 09/01/22
52-Week
18.43 +236.51%
on 01/21/22
69.06 -10.19%
on 11/21/22
+28.94 (+87.48%)
since 12/01/21

Most Recent Stories

More News
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

ANGN : 0.8479 (-1.42%)
NBRV : 2.15 (-4.45%)
ASLN : 0.5500 (-1.58%)
IMCR : 62.45 (-0.58%)
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.

ANGN : 0.8479 (-1.42%)
AXSM : 72.92 (+0.87%)
ASLN : 0.5500 (-1.58%)
IMCR : 62.45 (-0.58%)
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

ANGN : 0.8479 (-1.42%)
EDIT : 10.43 (-1.60%)
ASLN : 0.5500 (-1.58%)
IMCR : 62.45 (-0.58%)
Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be Sustainable

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks...

IMCR : 62.45 (-0.58%)
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

ANGN : 0.8479 (-1.42%)
ASLN : 0.5500 (-1.58%)
IMVT : 13.26 (+1.14%)
IMCR : 62.45 (-0.58%)
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

AVEO : 14.86 (-0.60%)
QURE : 26.87 (+1.55%)
ETON : 3.00 (-0.66%)
IMCR : 62.45 (-0.58%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 14.86 (-0.60%)
ETON : 3.00 (-0.66%)
IMCR : 62.45 (-0.58%)
PALI : 3.88 (-0.26%)
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

ANGN : 0.8479 (-1.42%)
SNDX : 23.67 (-1.21%)
BPMC : 48.22 (+0.90%)
IMCR : 62.45 (-0.58%)
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%

The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward...

IMCR : 62.45 (-0.58%)
bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

AVEO : 14.86 (-0.60%)
BLUE : 7.71 (-1.03%)
ETON : 3.00 (-0.66%)
IMCR : 62.45 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 69.64
2nd Resistance Point 66.81
1st Resistance Point 64.81
Last Price 62.45
1st Support Level 59.98
2nd Support Level 57.15
3rd Support Level 55.15

See More

52-Week High 69.06
Last Price 62.45
Fibonacci 61.8% 49.72
Fibonacci 50% 43.74
Fibonacci 38.2% 37.77
52-Week Low 18.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar